VacZine Analytics  
MarketVIEW: Klebsiella pneumoniae vaccines

Published: December 2022

Klebsiella pneumoniae is an encapsulated, Gram-negative non-motile bacterium of the enterobacterales family which typically colonizes the oropharynx and gastrointestinal (GI) tract. The classical form of Kp is mainly a opportunistic nosocomial/ICU pathogen which causes infections in immunocompromised or at risk individuals with comorbidities. Common Kp-related infections include pneumonia, urinary tract infection (UTI), pneumonia, intraabdominal infection, bloodstream infection (BSI) and meningitis. A hypervirulent form (hvKp) is capable of causing community-acquired infections, often in healthy individuals, with significant morbidity and mortality. In the developing world, Kp is major cause of neonatal sepsis being responsible for 124,000 deaths [89,000-167,000] in 2019 (GBD 2019). Worldwide (all syndromes) Kp caused 790,000 deaths [571-1,060,000] in 2019 being the 4th leading bacterial cause. Kp exhibit a high degree of antimicrobial resistance. Carbapenem (CRE) and ESBL-producing Kp are considered a critical threat by the World Health Organisation (WHO).

A prophylactic Klebsiella pneumoniae vaccine could prevent invasive disease in a number of target populations both in Western developed countries and the developing world e.g., GAVI-assisted countries. Several approaches are ongoing in both preclinical and clinical development with the most advanced being the GSK/LimmaTECH Bio Kleb4V (GSK4429016A), a subunit conjugate approach which recently completed a Phase 1/2 study [NCT04959344]. Other earlier potential approaches are being pursued by GSK/Affinivax, Syntiron, Vaxdyn and Omniose.

This MarketVIEW product is a comprehensive Executive Presentation (>225 slides, .pdf) and interactive MS-Excel forecast model (120 worksheets, .xls) which investigate the scenario-based uptake and commercial potential of Klebsiella pneumoniae vaccines across key target groups in 118 nations (public/private) worldwide including HI income and GAVI/developing world countries. A thorough review of latest disease background/epidemiology/resistance trends data is presented along with discussion of latest understanding of vaccinology/R&D competitor landscape. The analysis contains an in-depth commercial assessment of potential Klebsiella pneumoniae vaccine profiles with discussion around target population rationale, potential uptake, pricing and clinical development feasibility/issues

THIS PRODUCT IS A SUMMARY PRESENTATION (~225 slides, .pdf) + 1 scenario-based interactive MS Excel Workbook(s)
Photo credit(s): Zach-vessels (@unsplash license)

To order please contact your region account manager, buy "on-line" or order direct at: orders@vaczine-analytics.com

CAT No: CONTENTS: PURCHASE:
VAMV087 Click here>> CONTACT US

*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW. For UK orders VAT will be added at 20%. On-line prices may include discounts and are converted from list price in US dollars (subject to currency fluctuations). Please review the TERMS and CONDITIONS of purchase.

Return to main list>> Questions about this report?






© 2022 VacZine Analytics. All rights reserved. Disclaimer | Privacy | Terms and conditions. hosted by chillydomains